Key result
Diosgenin mitigated hypoxia-reoxygenation injury in H9c2 cardiomyoblast cells by significantly improving cell survival and decreasing lactate dehydrogenase release.
Why the study?
Does diosgenin protect H9c2 cardiomyoblast cells from hypoxia-reoxygenation injury?
Does diosgenin protect H9c2 cardiomyoblast cells from hypoxia-reoxygenation injury?
Diosgenin mitigates hypoxia-reoxygenation injury in cardiomyoblast cells by modulating pro-survival and pro-death pathways.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for diosgenin in ischemia-reperfusion injury; requires in vivo validation before any clinical consideration.
BACKGROUND: Diosgenin, a steroidal saponin from plants, exhibits many biological potentials. Herein, the cardioprotective role of diosgenin is studied. MATERIALS AND METHODS: The effect of diosgenin, isolated from Dioscorea bulbifera, was studied on hypoxia-reoxygenation (HR) in H9c2 cardiomyoblast cells. The amount of diosgenin in the plant extract was analyzed by high-performance thin layer chromatography using a solvent system comprising of chloroform:methanol:acetic acid:formic acid (13:4.5:1.5:1). Cardioprotection was checked by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Further, the release of lactate dehydrogenase, an enzyme released during cell death was checked. The proteins responsible for cell death (Bax) and cell survival (Bcl-2, hemeoxygenase-1 and Akt) were analyzed using Western blot to check the cardioprotective role of diosgenin. CONCLUSION: Supplementation of diosgenin mitigates HR injury, thereby exhibiting cardioprotective potential. SUMMARY: The cardioprotective effect of Diosgenin was evidenced from the improved cell survival after hypoxia-reoxygenation injury demonstrated through MTT cell survival assay.The release of lactate dehydrogenase, an enzyme released during cell death was decreased by Diosgenin.Diosgenin upregulated the pro-survival molecules like B-cell lymphoma 2 (Bcl-2), heme oxygenase-1 and the phosphorylation of ATK (at serine 473); and at the same time pro-.death molecules like Bax was downregulated.Thus, Diosgenin as a plant based steroidal saponin is confirmed to mitigate ischemic reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Vasanthi et al. (2016) studied Hypoxia-reoxygenation injury. Diosgenin vs. Ethanol + hypoxia-reoxygenation or hypoxia-reoxygenation alone was evaluated on Cell survival (MTT assay) and cell death (LDH release) (p=<0.05). Diosgenin mitigated hypoxia-reoxygenation injury in H9c2 cardiomyoblast cells by significantly improving cell survival and decreasing lactate dehydrogenase release.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: